-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-514730-21-00
5
2025-07-01
Bacterial infections and mycoses
-
2024-518771-66-00
9
2025-07-01
Hepatoblastoma, Rhabdomyosarcoma
-
2024-514539-67-00
4
2025-06-27
Systemic Sclerosis
-
2024-513111-27-00
5
2025-06-26
Psoriatic Arthritis
-
2025-520705-12-00
4
2025-06-24
Colitis Ulcerative
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2023-503723-26-00
6
2025-06-04
Patients undergoing allogeneic HSCT, for hematological malignancy, fol
-
2024-517457-27-00
5
2025-06-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-509391-42-00
11
2025-06-02
Chron's Disease
-
2024-518863-36-00
1
2025-05-27
Human Papilloma virus
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-517147-31-00
9
2025-05-23
Tumours, Gynecological
-
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
-
2024-517584-23-00
9
2025-05-16
Duchenne Muscular Dystrophy
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2024-513959-33-00
4
2025-05-13
Asthma
-
2024-516605-23-00
5
2025-05-12
relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-516447-12-00
6
2025-04-30
Systemic infections
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis